Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Patrick Berkovic, MD
CONTACT
Els Wauters, MD, PhD
CONTACT
Lead
Universitaire Ziekenhuizen KU Leuven
The (repeated) use of LAT to ≤ 3 OP lesions with continuation of first-line osimertinib, is endorsed by international guidelines (NCCN, ESMO). In this phase IIb prospective non-randomized observational trial, we want to document the benefit of LAT in this patient cohort.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
